MBIO MUSTANG BIO, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1680048 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-51.1%
TTM EPS YoY92.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-43.1%
ROA-20.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets55.1%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.29x
Accruals ratio6.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | — | $7.56M | $40.51M | $62.48M | $49.86M |
| SG&A expense | $3.95M | $4.13M | $9.69M | $12.21M | $11.02M |
| Operating income | -$2.43M | -$16.25M | -$49.26M | -$76.16M | -$66.72M |
| Interest expense | — | $5,000 | $4.11M | $3.36M | $15,000 |
| Pretax income | -$1.92M | -$15.75M | — | — | — |
| Income tax | $27,000 | — | — | — | — |
| Net income | -$1.92M | -$15.75M | -$51.60M | -$77.53M | -$66.37M |
| EBITDA | -$2.40M | -$15.57M | -$47.40M | -$73.44M | -$64.56M |
| EPS (basic) | -0.39 | -38.57 | -299.95 | -10.09 | -0.76 |
| EPS (diluted) | -0.39 | -38.57 | -299.95 | -10.09 | -0.76 |
| Weighted avg. shares (diluted) | 4.91M | 609,696 | 172,031 | 7.68M | 87.89M |
| Balance sheet | |||||
| Cash & equivalents | $17.27M | $6.84M | $6.98M | $76.66M | $110.62M |
| Current assets | $17.59M | $8.61M | $11.35M | $78.85M | $111.71M |
| PP&E, net | $0 | $371,000 | $3.25M | $8.44M | $11.05M |
| Total assets | $17.59M | $9.31M | $17.74M | $92.42M | $125.17M |
| Current liabilities | $7.91M | $12.61M | $15.37M | $15.11M | $10.81M |
| Total liabilities | $8.06M | $13.18M | $17.62M | $46.15M | $12.77M |
| Shareholders' equity | $9.53M | -$3.87M | $123,000 | $46.27M | $112.40M |
| Shares outstanding | — | — | — | — | 93.58M |
| Cash flow statement | |||||
| Operating cash flow | -$5.26M | -$11.41M | -$49.48M | -$65.07M | -$53.67M |
| Capital expenditure | — | $0 | $64,000 | $2.71M | $3.99M |
| Free cash flow | — | -$11.41M | -$49.54M | -$67.78M | -$57.65M |
| Investing cash flow | $1.17M | $0 | $5.89M | -$2.95M | -$5.37M |
| Financing cash flow | $14.53M | $11.27M | -$26.08M | $34.06M | $70.85M |
| Depreciation & amortization | $34,000 | $671,000 | $1.86M | $2.72M | $2.17M |
| Stock-based compensation | $129,000 | -$450,000 | $568,000 | $2.28M | $3.31M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.